Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-0189 with or without Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04502706Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GS-0189 in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by Gilead Sciences. Primary endpoint: Treatment-Emergent Adverse Events at 11 months. Started Nov 2020; status: terminated.
02
Drugs
GS-0189
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04502706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502706.